Roberto Pili

List of Publications by Year
in descending order

50 papers	3,122 citations	201674 27 h-index	197818 49 g-index
51 all docs	51 docs citations	51 times ranked	5396 citing authors

#	Article	IF	Citations
1	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 rgBT /Overlock 10	13.7	529
2	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 5187-5201.	7.0	288
3	Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study. Molecular Cancer Therapeutics, 2010, 9, 1525-1535.	4.1	160
4	Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models. PLoS ONE, 2012, 7, e30815.	2.5	158
5	CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381.	3.0	138
6	Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model. Clinical Cancer Research, 2007, 13, 4201-4208.	7.0	111
7	Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer. Oncotarget, 2013, 4, 2451-2461.	1.8	110
8	Platelets Take Up the Monoclonal Antibody Bevacizumab. Clinical Cancer Research, 2007, 13, 5341-5347.	7.0	105
9	Combination Strategy Targeting the Hypoxia Inducible Factor-1Î± with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 3589-3597.	7.0	105
10	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 944.	7.1	86
11	Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 4538-4546.	7.0	82
12	Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models. Molecular Cancer Therapeutics, 2015, 14, 101-110.	4.1	82
13	Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. British Journal of Cancer, 2017, 116, 874-883.	6.4	78
14	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2636-2643.	1.6	77
15	Epigenetic Modulation of Retinoic Acid Receptor Î²2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma. Clinical Cancer Research, 2005, 11, 3535-3542.	7.0	76
16	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 1356-1363.	7.0	71
17	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research, 2017, 23, 7199-7208.	7.0	68
18	EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Research, 2017, 77, 6651-6666.	0.9	66

#	Article	IF	Citations
19	Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radical Biology and Medicine, 2018, 115, 447-457.	2.9	65
20	Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications. Molecular Cancer Therapeutics, 2015, 14, 513-522.	4.1	64
21	Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics, 2016, 8, 415-428.	2.1	60
22	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5977-5989.	7.0	58
23	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British Journal of Cancer, 2020, 123, 1590-1598.	6.4	57
24	Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model. Oncotarget, 2015, 6, 31233-31240.	1.8	55
25	Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. OncoImmunology, 2012, 1, 948-950.	4.6	48
26	Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts. PLoS ONE, 2014, 9, e112371.	2.5	45
27	Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. Molecular Cancer Therapeutics, 2019, 18, 1947-1960.	4.1	29
28	Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma. Cancer Research, 2018, 78, 2886-2896.	0.9	27
29	Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience, 2014, 1, 844-853.	2.2	26
30	Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2012, 11, 383-392.	4.1	22
31	Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget, 2017, 8, 26312-26322.	1.8	22
32	Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget, 2015, 6, 24376-24392.	1.8	18
33	Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. OncoTargets and Therapy, 2014, 7, 223.	2.0	16
34	Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy. Journal of Visualized Experiments, 2014, , .	0.3	15
35	Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer. PLoS ONE, 2014, 9, e103680.	2.5	11
36	Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1-e9.	1.9	11

#	Article	IF	Citations
37	Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Investigational New Drugs, 2020, 38, 1108-1116.	2.6	11
38	Real-Time Multiplex Kinase Phosphorylation Sensors in Living Cells. ACS Sensors, 2017, 2, 1225-1230.	7.8	10
39	Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 147-156.	4.1	10
40	Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 2572-2572.	1.6	10
41	Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis. Oncoscience, 2014, 1, 609-613.	2.2	10
42	Combined inhibition of Refâ€1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour coâ€culture models. Journal of Cellular and Molecular Medicine, 2021, 25, 784-800.	3.6	9
43	Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. Clinical Genitourinary Cancer, 2017, 15, e517-e519.	1.9	5
44	Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intraâ€and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. Molecular Carcinogenesis, 2017, 56, 2527-2537.	2.7	5
45	Plasmacytoid urothelial carcinoma: A clinicopathological study.. Journal of Clinical Oncology, 2018, 36, 482-482.	1.6	5
46	Low-protein diet in cancer: ready for prime time?. Nature Reviews Endocrinology, 2018, 14, 384-386.	9.6	3
47	Epigenetic Dysregulation in Advanced Kidney Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 399-406.	2.0	3
48	A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clinical Genitourinary Cancer, 2017, 15, 642-651.e1.	1.9	1
49	A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naÃ¯ve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.. Journal of Clinical Oncology, 2019, 37, 561-561.	1.6	1
50	Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients.. Journal of Clinical Oncology, 2018, 36, e16585-e16585.	1.6	0